Leavenworth, check out their titles. I think like 6 out of the 7 clinical advisers are heads of rheumatology at major hospitals and universities. Cha Ching when they announce 9200 for that indication and cha-ching for Polymyositis and Dermamysositis. The PM and DM trial is big because rheumatology doctors currently prescribe off-label when they have a good drug. Rheumatology market is north of $10 billion. Yes, these guys know exactly what they're building here. A monster money machine. 2s will be a joke in less than a year, maybe less than a month.
Interesting. So a strong BP partner on 9200 should really have an effect. I believe that will happen in due time. Thanks eddy.
Last trip down elliot wave 5 downtrend before new trend starts. it is significantly shorter than wave 3.
Just might. Think we get news cycle soon. Keep it there. It won't stay there long if it gets there at all.
Leavenworth, good thinking. Don't budge on your bid. I think you'll get it. I've got my whole fill of IDRA now. My plan is simple. Wait for my number, which is 37 in about 2-5 years. The rest is noise I can live with. IDRA is a once-in-a-lifetime opportunity sitting here at gift prices. In a couple years, we'll no longer have curious george and first lady roddy mcdowall in the white house, and the economy will soar again with a biz-friendly government. Curious george will be out struggling to run a lemonade stand.
IDRA knows how much 8400 is kicking #$%$. Just a matter of when they start sharing the medical miracles of WM and DLBCL patients. Don't forget 9200 indications. Tomorrow? Friday? Next week? Who knows but it's coming.
No, they haven't. With cc tomorrow, now would be the time to show off some new WM and DLBCL data since they're open-label. They also said they prefer scientific symposiums to present data, which is why they withhold data (ASH requirement is NEW unpublished data). Late-breaking abstracts will be announced Nov 17 if not today. I'd be surprised to not see one accepted for presentation, and that would be the reason for cc on Friday. Accepted abstracts were notified weeks ago, but public announcement by ASH is today, and IDRA cc is tomorrow.
Here's the first one:
IMO-8400, an Antagonist of Toll-like Receptors 7, 8, and 9, in Development for Genetically Defined B-Cell Lymphomas: Safety and Activity in Phase 1 and Phase 2 Clinical Trials
Session name: 624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster II
Poster presentation time:Sunday, December 7, 2014, 6:00 - 8:00 p.m. PST
Here's the 2nd one:
Novel Approach to the Potential Treatment of Patients with B-Cell Lymphomas Harboring the MYD88 L265P Mutation: Combination Treatment with TLR Antagonist and Rituximab
Session name: 625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents I
Oral presentation time:Monday, December 8, 2014, 3:30 p.m. PST
Intratumoral Injection of IMO-2055, a Novel Toll-like Receptor 9 Agonist, with Ipilimumab INDUCES A SYSTEMIC TUMOR-SPECIFIC IMMUNE RESPONSE
Session name: Poster Session A
Poster presentation time: Tuesday, December 2, 1:15 - 3:30 p.m. EST
Lot of good data being rolled out in weeks ahead. A drug that shrinks tumors. Not bad at all. If anyone is on the fence, get off now because institutional buys are about to increase.
Lou Brenner, M.D., CMO, will be delivering this presentation along with Robert Arbeit, M.D., VP-Clinical Development, and Timothy Sullivan, Ph. D.VP-Development Programs and Alliance Management. The A Team.
Wait til the news ripples out, shorts will cover quite quickly as new buyers swarm in. Gonna happen without a doubt very soon here.
Psoriasis results at ASH as part of proof of safety and efficacy. Here is part of the abstract:
"In the Phase 2 trial, clinical proof of mechanism was demonstrated by increased frequency of improvements in psoriasis disease activity in IMO-8400-treated patients across multiple dose levels relative to placebo-treated patients.
Conclusion. Antagonism of TLRs 7 and 9 is a novel, scientifically-driven approach to the treatment of B-cell malignancies characterized by presence of the MYD88 L265P oncogenic mutation. IMO-8400, a clinical-stage drug candidate, was well tolerated in clinical trials conducted in healthy subjects and patients with psoriasis, having demonstrated no myelosuppression or any pattern of hematological or other toxicity in 12-week treatment regimens."
"Preclinical data presented at AACR 2014, including from xenograft tumor studies, show that IMO-8400 inhibits cell signaling and REDUCES TUMOR GROWTH in WM and DLBCL models harboring the MYD88 L265P mutation. Clinical data from 2 completed trials of IMO-8400 are presented here."
Sentiment: Strong Buy